Literature DB >> 8889328

Vaccine for prophylaxis and immunotherapy, Brazil.

O Genaro1, V P de Toledo, C A da Costa, M V Hermeto, L C Afonso, W Mayrink.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8889328     DOI： 10.1016/0738-081x(96)00040-5

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN： 0738-081X            Impact factor:   3.541


× No keyword cloud information.
  17 in total

Review 1.  Kinetoplastids: related protozoan pathogens, different diseases.

Authors:  Ken Stuart; Reto Brun; Simon Croft; Alan Fairlamb; Ricardo E Gürtler; Jim McKerrow; Steve Reed; Rick Tarleton
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

2.  Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates.

Authors:  S S Kashino; C Abeijon; L Qin; K A Kanunfre; F S Kubrusly; F O Silva; D L Costa; D Campos; C H N Costa; I Raw; A Campos-Neto
Journal:  Parasite Immunol       Date:  2012-07       Impact factor: 2.280

3.  Parasites and immunotherapy: with or against?

Authors:  Hossein Yousofi Darani; Morteza Yousefi; Marzieh Safari; Rasool Jafari
Journal:  J Parasit Dis       Date:  2014-08-31

Review 4.  The development and clinical evaluation of second-generation leishmaniasis vaccines.

Authors:  Malcolm S Duthie; Vanitha S Raman; Franco M Piazza; Steven G Reed
Journal:  Vaccine       Date:  2011-11-12       Impact factor: 3.641

5.  Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis.

Authors:  Vanitha S Raman; Ajay Bhatia; Alex Picone; Jacqueline Whittle; Hilton R Bailor; Joanne O'Donnell; Sowmya Pattabhi; Jeffrey A Guderian; Raodoh Mohamath; Malcolm S Duthie; Steven G Reed
Journal:  J Immunol       Date:  2010-07-02       Impact factor: 5.422

6.  Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.

Authors:  A Campos-Neto; R Porrozzi; K Greeson; R N Coler; J R Webb; Y A Seiky; S G Reed; G Grimaldi
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

7.  Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.

Authors:  Robert G Schaut; Tara L Grinnage-Pulley; Kevin J Esch; Angela J Toepp; Malcolm S Duthie; Randall F Howard; Steven G Reed; Christine A Petersen
Journal:  Vaccine       Date:  2016-09-21       Impact factor: 3.641

8.  Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

Authors:  Rhea N Coler; Yasir A W Skeiky; Karen Bernards; Kay Greeson; Darrick Carter; Charisa D Cornellison; Farrokh Modabber; Antonio Campos-Neto; Steven G Reed
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

9.  Vaccine Development Against Leishmania donovani.

Authors:  Amrita Das; Nahid Ali
Journal:  Front Immunol       Date:  2012-05-15       Impact factor: 7.561

10.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.